HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ad Firm Behind Bogus Weight Loss Claims Fined $2M: Health And Wellness Industry News

This article was originally published in The Rose Sheet

Executive Summary

FTC and Maine would collect $2m under a settlement on complaint that Marketing Architects created ads for a weight loss supplement firm already targeted by FTC for false claims; Long Life Unlimited warned on claims; and UK catalog claims healing powers for meristem.

You may also be interested in...



'Free Trial' Plus False Claims Equals More FTC Enforcement In Supplement Market

FTC on consecutive days announced court order closing a California business allegedly charging consumers for products and enrolling them in negative-option continuity plans without their consent after they responded to bogus free trial online offers, and started mailing 16,596 checks totaling more than $750,000 to consumers who bought deceptively marketed supplements from a Maine firm that also lured customers with a free trial pitch.

Health, Beauty And Wellness News: NPA On NIS, AHPA JAMA Letter, Zero Recall Two

NPA wants to work with FDA to develop broader, more transparent medical food definition; FTC FY 2018 report notes enforcements against supplement firms making false claims of memory and cognitive benefits; Zero Xtreme recalled for second time in two years after found containing sibutramine; and more news.

Essential Oil Sleep Claims In Hot Water With UK Advertising Regulator

UK Advertising Standards Authority advised Puressentiel not to make ad claims reserved for licensed medicinal products. Puressentiel argued its products aren't medicinal, but still provided efficacy studies, which ASA declined to review.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS121456

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel